Article Data

  • Views 1220
  • Dowloads 164

Original Research

Open Access

Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?

  • U Chul Ju1,†
  • Woo Dae Kang1,†
  • Seok Mo Kim1,*,

1Department of Obstetrics and Gynecology, Chonnam National University Medical School, 61469 Gwangju, Republic of Korea

DOI: 10.31083/j.ejgo4302022 Vol.43,Issue 2,April 2022 pp.169-174

Submitted: 09 December 2021 Accepted: 20 January 2022

Published: 15 April 2022

*Corresponding Author(s): Seok Mo Kim E-mail: seokmo2001@hanmail.net

† These authors contributed equally.

Abstract

Objective: This study aimed to investigate the endometrial pathology findings and to determine the appropriate diagnostic approach to assess for potential endometrial malignancy or premalignant pathology in women treated with tamoxifen for breast cancer. Methods: We retrospectively reviewed the medical records of 162 patients taking tamoxifen and who underwent endometrial biopsy. We compared the clinical features of the patients with endometrial intraepithelial neoplasia or cancer (EIN/EC group) and the patients with other pathologic results (others group). Results: EIN or EC was found in ten patients (6.2%). While 70.0% of EIN/EC group received tamoxifen treatment for more than 3 years, 71.7% of the others group received less than 3 years (p < 0.001). Regardless of the presence of vaginal bleeding, EIN/EC was not found in patients with endometrial thickness (ET) <5 mm on transvaginal ultrasonography (TV-US). When ET was 5 mm, the incidence rates of EIN/EC were only 2.9% in asymptomatic patients and 11.6% in symptomatic patients, respectively (p = 0.002). When ET was 8 mm, the incidence rates of EIN/EC were 3.8% in asymptomatic patients and 12.0% in symptomatic patients, respectively (p = 0.002). When ET was <8 mm, EIN/EC was not found in patients without vaginal bleeding, while EIN/EC was found in 7.1% of patients with vaginal bleeding. Conclusions: Indiscriminate endometrial evaluation should be avoided in women treated with tamoxifen for breast cancer. Patients taking tamoxifen who experience vaginal bleeding and have a thick endometrium (5 mm) on TV-US, they should undergo endometrial biopsy.


Keywords

breast cancer; tamoxifen; endometrial pathology; vaginal bleeding; endometrial thickness

Cite and Share

U Chul Ju,Woo Dae Kang,Seok Mo Kim. Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?. European Journal of Gynaecological Oncology. 2022. 43(2);169-174.

References

[1] Jung K, Won Y, Kong H, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Research and Treatmen. 2018; 50: 303–316.

[2] Yarnold J. Early and Locally Advanced Breast Cancer: Diag-nosis and Treatment National Institute for Health and Clinical Excellence Guideline 2009. Clinical Oncology. 2009; 21: 159–160.

[3] Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstetrics and Gynecology. 2014;123: 1394–1397.

[4] Ismail SM. Pathology of endometrium treated with tamoxifen. Journal of Clinical Pathology. 1994; 47: 827–833.

[5] Saccardi C, Gizzo S, Patrelli TS, Ancona E, Anis O, Di Gangi S, et al. Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study. Endocrine-Related Cancer. 2013; 20: 455–462.

[6] Fung MFK, Reid A, Faught W, Le T, Chenier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecologic Oncology. 2003; 91: 154–159.

[7] Cohen I, Perel E, Flex D, Tepper R, Altaras MM, Cordoba M, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. Journal of Clinical Pathology. 1999; 52: 278–282.

[8] Achiron R, Lipitz S, Sivan E, Goldenberg M, Horovitz A, Frenkel Y, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound in Obstetrics & Gynecology. 1995; 6: 116–120.

[9] Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994; 343: 1318–1321.

[10] Schweikart KM, Eldridge SR, Safgren SL, Parman T, Reid JM, Ames MM, et al. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats. Toxicologic Pathology. 2014; 42: 1188–1196.

[11] Marshall K, Senior J. A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat. British Journal of Pharmacology. 1987; 92: 429–435.

[12] Peters‐Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Research and Treatment. 1999; 54: 255–260.

[13] Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 1998; 82: 1698–1703.

[14] Bertelli G, Venturini M, Mastro LD, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Research and Treatment. 1998; 47: 41–46.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top